Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3242Biotechnology

$18.00 +$0.14 (+0.78%)

Pre-market · Oct 8, 8:50 am ET · After hours $18.00 0.00%

Open$17.72

Prev close$17.86

Day range$17.70 – $18.35

Volume294.1K

Market cap$1.00B

P/E (TTM)–

Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership89.8%-0.50 pts vs. prior quarter

Institutions holding144+3 vs. prior quarter

Insider trades (recent)7 buys / 5 sellsNet buying

Short interest5.85% of floatDays to cover 11.5 · as of 15 Sep 2026

Short-sale volume share22.2%5-day average of daily volume

Short-sale volume as % of daily volume

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$724.1K (9 inflow days, 11 outflow days).

Net flow by order size, last 20 sessions

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 46.7% of shares outstanding.

Largest holders

Eli Lilly and Company11.41%
EcoR1 Capital, LLC10.56%
Vida Ventures Advisors, LLC10.48%
MPM BioImpact LLC8.69%
CHI Advisors LLC5.52%
T. Rowe Price Group, Inc.5.06%
Blue Owl Credit Private Fund Advisors LLC4.37%
BlackRock4.10%

By investor type

VC/PE Fund30.83%
Hedge Fund23.51%
Mutual Fund23.03%
Public Company11.98%
Individual/Insider0.46%
Family Office/Trust0.20%
Private Company0.11%
Insurance Company0.08%

Reported short interest has fallen from 5.98% to 5.85% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

Holder	Type	Period	Share change	New stake
Nuveen Asset Management LLC	Insurance Company	2026/Q3	+41,719	0.1%
TCG Crossover Management, LLC	VC/PE Fund	2026/Q3	+696,560	1.3%
BlackRock	Mutual Fund	2026/Q3	+166,231	4.1%
Barclays PLC	Public Company	2026/Q3	+146,282	0.3%
Renaissance Technologies Corp.	Hedge Fund	2026/Q3	+95,400	0.2%
Polen Capital Management, LLC	Mutual Fund	2026/Q3	+63,514	0.1%
Tidal Investments LLC	Mutual Fund	2026/Q3	+57,059	0.1%
State Street Global Advisors	Mutual Fund	2026/Q3	+55,757	0.9%
Raymond James Financial, Inc.	Public Company	2026/Q3	+50,464	0.1%
AQR Capital Management	Hedge Fund	2026/Q3	+47,504	0.1%
Quantinno Capital Management LP	Mutual Fund	2026/Q3	+46,887	0.1%
Great Lakes Advisors, LLC	Mutual Fund	2026/Q3	+43,612	0.1%
Mirador Capital Partners, LP	Mutual Fund	2026/Q3	+40,124	0.1%
Merrill Lynch, Pierce, Fenner & Smith Incorporated	Private Company	2026/Q3	+39,308	0.1%
Squarepoint OPS LLC	Hedge Fund	2026/Q3	+38,381	0.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

Date	Insider	Title	Transaction	Shares	Price	Held after
22 Sep 2026	Akos Czibere	Chief Medical Officer	Derivative Exercise and Sale	-12,500	$21.03	–
19 Jul 2026	Ken Herrmann	Chair of Scientific Advisory Board & Independent Director	Derivative Exercise and Sale	-4,856	$24.56	–
16 Jul 2026	Ken Herrmann	Chair of Scientific Advisory Board & Independent Director	Derivative Exercise and Sale	-3,065	$25.21	–
7 Jul 2026	Shulamit Ron-Bigger	Chief Operating Officer	Derivative Exercise and Sale	-50,000	$28.75	–
7 Jul 2026	Akos Czibere	Chief Medical Officer	Derivative Exercise and Sale	-50,000	$28.71	–
11 Jan 2026	MPM BioImpact LLC		Private Acquisition	+1,112,777	$18.00	10,260,064
11 Jan 2026	MPM BioImpact LLC		Derivative Exercise and Retained	+8,208,187	–	10,260,064
11 Jan 2026	Eli Lilly and Company		Initial Statement of Beneficial	+0	–	6,344,114
11 Jan 2026	Lloyd Segal	Independent Director	Derivative Exercise and Retained	+19,631	–	19,631
11 Jan 2026	EcoR1 Capital, LLC		Private Acquisition	+2,222,222	$18.00	4,824,469
11 Jan 2026	EcoR1 Capital, LLC		Derivative Exercise and Retained	+2,602,247	–	4,824,469
11 Jan 2026	Vida Ventures Advisors, LLC		Private Acquisition	+835,000	$18.00	5,829,212
11 Jan 2026	Vida Ventures Advisors, LLC		Derivative Exercise and Retained	+4,994,212	–	5,829,212
7 Jan 2026	MPM BioImpact LLC		Initial Statement of Beneficial	+0	–	597,393
7 Jan 2026	Todd Foley	Chairperson	Initial Statement of Beneficial	+0	–	37,866
7 Jan 2026	Helen Kim	Independent Director	Initial Statement of Beneficial	+0	–	37,866
7 Jan 2026	Michael Sherman	Independent Director	Initial Statement of Beneficial	+0	–	93,846
7 Jan 2026	Lloyd Segal	Independent Director	Initial Statement of Beneficial	+0	–	6,489
7 Jan 2026	Mary Thistle	Independent Director	Initial Statement of Beneficial	+0	–	93,846
7 Jan 2026	Matthew Roden	Chief Executive Officer	Initial Statement of Beneficial	+0	–	2,149,409

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report date	Shares short	% of float	Days to cover
15 Sep 2026	3,252,475	5.8%	11.5
31 Aug 2026	3,175,040	5.7%	10.4
14 Aug 2026	3,447,126	6.2%	15.0
31 Jul 2026	3,470,122	6.3%	12.8
15 Jul 2026	3,741,161	6.8%	6.3
30 Jun 2026	3,306,972	6.0%	5.0

Discussion

No comments yet — be the first to weigh in on AKTS.